168 related articles for article (PubMed ID: 38030892)
41. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma.
Yoo C; Yoon DH; Jo JC; Yoon S; Kim S; Lee BJ; Huh J; Lee SW; Suh C
Ann Hematol; 2014 Jun; 93(6):995-1000. PubMed ID: 24441948
[TBL] [Abstract][Full Text] [Related]
42. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Wei W; Wu P; Li L; Zhang ZH
Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
[TBL] [Abstract][Full Text] [Related]
43. Pegaspargase Combined with Concurrent Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Two-Center Phase II Study.
Wang H; Wang L; Li C; Wuxiao Z; Chen G; Luo W; Lu Y
Oncologist; 2020 Nov; 25(11):e1725-e1731. PubMed ID: 32627928
[TBL] [Abstract][Full Text] [Related]
44. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
[TBL] [Abstract][Full Text] [Related]
45. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
[TBL] [Abstract][Full Text] [Related]
47. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
[TBL] [Abstract][Full Text] [Related]
48. Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.
Albano D; Bosio G; Re A; Pagani C; Giubbini R; Bertagna F
Leuk Lymphoma; 2019 Feb; 60(2):326-333. PubMed ID: 29966473
[TBL] [Abstract][Full Text] [Related]
49. Positron emission tomography/computed tomography in the diagnosis, staging, and prognostic evaluation of natural killer/T-cell lymphoma.
Ding JJ; Chen YL; Zhou SH; Zhao K
J Int Med Res; 2018 Dec; 46(12):4920-4929. PubMed ID: 30328364
[TBL] [Abstract][Full Text] [Related]
50. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma.
Casulo C; Schöder H; Feeney J; Lim R; Maragulia J; Zelenetz AD; Horwitz S
Leuk Lymphoma; 2013 Oct; 54(10):2163-7. PubMed ID: 23369041
[TBL] [Abstract][Full Text] [Related]
51. Primary Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma of Lower Limb Muscles on 18 F-FDG PET/CT.
Li C; Hu X
Clin Nucl Med; 2024 Jan; 49(1):e45-e46. PubMed ID: 37976527
[TBL] [Abstract][Full Text] [Related]
52. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of
Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
[TBL] [Abstract][Full Text] [Related]
54. The exact Deauville score, NABS score and high SUVmax predicts outcome in extranodal natural killer/T-cell lymphoma.
Huang HL; Ngam PI; Tan KM; Ng DCE; Lim ST; Chan JY
Ann Nucl Med; 2021 May; 35(5):557-568. PubMed ID: 33683545
[TBL] [Abstract][Full Text] [Related]
55. The predictive value of pre-treatment
Guo R; Xu P; Xu H; Miao Y; Li B
Leuk Lymphoma; 2020 Nov; 61(11):2659-2664. PubMed ID: 32573298
[TBL] [Abstract][Full Text] [Related]
56. Long-term outcomes and central nervous system relapse in extranodal natural killer/T-cell lymphoma.
Miyazaki K; Suzuki R; Oguchi M; Taguchi S; Amaki J; Maeda T; Kubota N; Maruyama D; Terui Y; Sekiguchi N; Takizawa J; Tsukamoto H; Murayama T; Ando T; Matsuoka H; Hasegawa M; Wada H; Sakai R; Kameoka Y; Tsukamoto N; Choi I; Masaki Y; Shimada K; Fukuhara N; Utsumi T; Uoshima N; Kagami Y; Asano N; Ejima Y; Katayama N; Yamaguchi M
Hematol Oncol; 2022 Oct; 40(4):667-677. PubMed ID: 35142384
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of
Sun N; Qiao W; Xing Y; Wang T; Yang J; Zhao J
Clin Transl Oncol; 2021 Aug; 23(8):1571-1576. PubMed ID: 33449269
[TBL] [Abstract][Full Text] [Related]
58. Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas.
Qian L; Yan M; Zhang W; Zhou D; Zhang Y; Huo L; Luo Y; Zhang Y; Hu S
Leuk Lymphoma; 2020 Apr; 61(4):927-933. PubMed ID: 31795794
[TBL] [Abstract][Full Text] [Related]
59. Extranodal NK/T-cell lymphoma with localized relapse in bone marrow of lower leg detected using PET-CT.
Nakamura T; Tatetsu H; Higuchi Y; Endo S; Shiraishi S; Kawanaka K; Imakane D; Sonoda M; Furuta R; Shichijo T; Honda Y; Karube K; Mikami Y; Nosaka K; Matsuoka M; Yasunaga JI
J Clin Exp Hematop; 2024; 64(1):45-51. PubMed ID: 38538318
[TBL] [Abstract][Full Text] [Related]
60.
Yang C; Wu W; Zhou H; Zhao S; Tian R; Xiang M; Zou L
Front Oncol; 2022; 12():894804. PubMed ID: 35965550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
